ChemoCentryx Inc
CCXI
Get informed when a big investor buys or sells
+ FollowMarket Cap$540.51M
Close$
$0.01
99.9% downside
Current Fair Value
99.9% downsideOvervalued by 99.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $540.51 Million |
|---|---|
| Enterprise Value | $539.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.01 |
| Beta | -1.17 |
| Outstanding Shares | 55,700,000 |
Return
| Return on Equity | -50.03% |
|---|---|
| Return on Assets | -31.76% |
| Return on Invested Capital | -14.13% |
Valuation & Multiples
| P/E Ratio | -5.35 |
|---|---|
| PEG | -1.68 |
| Price to Sales | - |
| Price to Book Ratio | 3.06 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -13.5 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 56.88%▲ 8.30% |
|---|---|
| Total Invested | $549.94M▲ 100.03% |
| Investors Holding | 73▲ 25.00% |
ESG Score
No data
About ChemoCentryx Inc
CEO: Thomas Schall